Suppr超能文献

肾细胞癌伴静脉瘤栓延伸患者中肿瘤栓子水平的预后意义。所有T3b期患者情况都一样吗?

Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?

作者信息

Moinzadeh Alireza, Libertino John A

机构信息

Department of Urology, Lahey Clinic, Burlington, Massachusetts, USA.

出版信息

J Urol. 2004 Feb;171(2 Pt 1):598-601. doi: 10.1097/01.ju.0000108842.27907.47.

Abstract

PURPOSE

We investigated the prognostic significance of venous tumor thrombus extension in patients with renal cell carcinoma with particular emphasis on 2 questions. Does the level of thrombus in the inferior vena cava (IVC) impact long-term survival? Is there a difference in long-term survival when tumor thrombus is in the renal vein versus the IVC for patients classified as T3b by 1997 TNM staging?

MATERIALS AND METHODS

Between July 1970 and July 2000, 153 patients underwent surgical resection. Cancer specific survival was determined for different tumor thrombus levels in a retrospective fashion.

RESULTS

Mean followup was 60 months with a range of 12 to 221. Level of tumor thrombus was renal vein (in 46), level I (in 68), level II (in 17) and level III (in 22). No demographic differences existed between the different levels including gender, age, perinephric extension, Fuhrman grade, percentage of metastatic disease and tumor size (Fisher's exact test). Patients with evidence of nodal disease or metastasis at surgery were eliminated from cancer specific survival analysis. The overall 10-year cancer specific survival for patients was 30%, 19% and 29% for level I, II and III, respectively. Patient survival at 5 and 10 years was not significantly different between the 3 IVC levels (p = 0.48). Ten-year survival of patients with renal vein involvement (66%) versus level I (29%) was significantly different (p = 0.0001).

CONCLUSIONS

The level of tumor thrombus in the IVC does not significantly effect long-term survival. Ten-year survival of patients classified as T3b is statistically different for patients having tumor thrombus in the renal vein compared to level I. Combining these 2 groups as T3b by the 1997 TNM staging may need to be reevaluated.

摘要

目的

我们研究了肾细胞癌患者静脉肿瘤血栓延伸的预后意义,特别关注两个问题。下腔静脉(IVC)内血栓水平是否影响长期生存?对于根据1997年TNM分期归类为T3b的患者,肿瘤血栓位于肾静脉与位于下腔静脉时,长期生存是否存在差异?

材料与方法

1970年7月至2000年7月期间,153例患者接受了手术切除。以回顾性方式确定不同肿瘤血栓水平的癌症特异性生存率。

结果

平均随访时间为60个月,范围为12至221个月。肿瘤血栓水平为肾静脉(46例)、I级(68例)、II级(17例)和III级(22例)。不同水平之间在人口统计学方面无差异,包括性别、年龄、肾周延伸、Fuhrman分级、转移疾病百分比和肿瘤大小(Fisher精确检验)。手术时有淋巴结疾病或转移证据的患者被排除在癌症特异性生存分析之外。I级、II级和III级患者的总体10年癌症特异性生存率分别为30%、19%和29%。3种下腔静脉水平患者的5年和10年生存率无显著差异(p = 0.48)。肾静脉受累患者的10年生存率(66%)与I级患者(29%)有显著差异(p = 0.0001)。

结论

下腔静脉内肿瘤血栓水平对长期生存无显著影响。对于归类为T3b的患者,肿瘤血栓位于肾静脉的患者与I级患者相比,10年生存率在统计学上有差异。1997年TNM分期将这两组合并为T3b可能需要重新评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验